ArticleFrontiers in aging neuroscience2025
Improvement of neuropsychological and cognitive functions in older adults through transcranial vibroacoustic stimulation: a double blind, randomized, comparative trial.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on 40 Hz sensory stimulation for the treatment of Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cognitive impairments are critical global public health issues. Recent research has focused on developing non-invasive methods for cognitive enhancement with the potential to slow cognitive decline. This study aimed to explore the effects of transcranial vibroacoustic stimulation (tVAS) on neuropsychological and cognitive functions in older adults. Methods: This double-blind, randomization, comparative trial applied tVAS at frequencies of 20 or 40 Hz for 30 min per day over an 8-week period using a novel tVAS device. Neuropsychological assessments, saliva cortisol levels, electroencephalography (EEG), and event-related potentials (ERP) were evaluated before and after the intervention. Results: Following the tVAS intervention, total scores on the consortium to establish a registry for Alzheimer's disease-Korean version (CERAD-K) 1 and 2 indicated a significant overall improvement in cognitive function in both the 20 and 40 Hz tVAS groups ( Discussion: Individual-level EEG and ERP analyses suggest that 40 Hz tVAS enhances neural plasticity, and early-stage sensory processing efficiency. Group-level comparisons further support the successful induction of gamma entrainment, potentially promoting brain network synchronization and increased sensitivity to high-frequency auditory stimuli. While the 40 Hz tVAS intervention demonstrated potential cognitive and affective benefits with favorable safety characteristics, larger-scale studies are needed to confirm its clinical applicability. Clinical trial registration: https://cris.nih.go.kr/, identifier registration KCT0010055.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.